[ {
  "@graph" : [ {
    "@id" : "http://bio2rdf.org/drugbank:DB00673",
    "http://bio2rdf.org/drugbank_vocabulary:ddi-interactor-in" : [ {
      "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285"
    } ]
  }, {
    "@id" : "http://bio2rdf.org/drugbank:DB01285",
    "http://bio2rdf.org/drugbank_vocabulary:ddi-interactor-in" : [ {
      "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285"
    } ]
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285",
    "@type" : [ "http://bio2rdf.org/drugbank_vocabulary:Drug-Drug-Interaction" ],
    "http://purl.org/dc/terms/identifier" : [ {
      "@value" : "drugbank_resource:DB00673_DB01285"
    } ],
    "http://purl.org/dc/terms/title" : [ {
      "@language" : "en",
      "@value" : "DDI between Aprepitant and Corticotropin - Aprepitant may increase the serum concentration of Corticosteroids (Systemic). Monitor for increased effects of systemic corticosteroids when coadmininistered with aprepitant; corticosteroid dose reduction may be necessary. The manufacturer of fosaprepitant (a prodrug of aprepitant) states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone. Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen."
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@language" : "en",
      "@value" : "DDI between Aprepitant and Corticotropin - Aprepitant may increase the serum concentration of Corticosteroids (Systemic). Monitor for increased effects of systemic corticosteroids when coadmininistered with aprepitant; corticosteroid dose reduction may be necessary. The manufacturer of fosaprepitant (a prodrug of aprepitant) states that oral dexamethasone doses should be reduced by 50% when coadministered with a fosaprepitant/aprepitant regimen to achieve dexamethasone concentrations similar to those achieved with dexamethasone alone. Dexamethasone doses used in clinical chemotherapy nausea/vomiting studies with aprepitant reflect this 50% decrease. Similarly, it is recommended that in order to achieve concentrations similar to those achieved with methylprednisolone alone, the intravenous methylprednisolone dose should be reduced by 25% and the oral methylprednisolone dose should be reduced by 50% when given together with a fosaprepitant/aprepitant regimen. [drugbank_resource:DB00673_DB01285]"
    } ]
  } ],
  "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#publicationInfo"
    } ]
  } ],
  "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#head"
}, {
  "@graph" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#assertion",
    "http://semanticscience.org/resource/SIO_000253" : [ {
      "@id" : "http://bio2rdf.org/drugbank_resource:bio2rdf.dataset.drugbank.R3"
    } ]
  } ],
  "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2018-03-30T11:13:01.377+02:00"
    } ],
    "http://purl.org/dc/terms/license" : [ {
      "@id" : "https://creativecommons.org/licenses/by-nc/4.0/"
    } ],
    "http://purl.org/nanopub/x/hasSignatureElement" : [ {
      "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#signature.MC0CFQCF6PW5uSW_"
    } ],
    "http://www.w3.org/ns/prov#wasGeneratedBy" : [ {
      "@id" : "https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11"
    } ]
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#signature.MC0CFQCF6PW5uSW_",
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIIBtzCCASwGByqGSM44BAEwggEfAoGBAP1/U4EddRIpUt9KnC7s5Of2EbdSPO9EAMMeP4C2USZpRV1AIlH7WT2NWPq/xfW6MPbLm1Vs14E7gB00b/JmYLdrmVClpJ+f6AR7ECLCT7up1/63xhv4O1fnxqimFQ8E+4P208UewwI1VBNaFpEy9nXzrith1yrv8iIDGZ3RSAHHAhUAl2BQjxUjC8yykrmCouuEC/BYHPUCgYEA9+GghdabPd7LvKtcNrhXuXmUr7v6OuqC+VdMCz0HgmdRWVeOutRZT+ZxBxCBgLRJFnEj6EwoFhO3zwkyjMim4TwWeotUfI0o4KOuHiuzpnWRbqN/C/ohNWLx+2J6ASQ7zKTxvqhRkImog9/hWuWfBpKLZl6Ae1UlZAFMO/7PSSoDgYQAAoGAETGrDm8R3KfndKRj7ttr3jVhhstI6/2Ey0ER9F5kdx7Hrd6eolq7yWzPzf2H754tdZxICzxYcdawBbL2ZUzFjWwXTNUQC3+e6evKPJyNELubnZcA+8TxIIwicBnw3Ku6mSeI8SUVr5SBV1VeJoSu/ahldv562IdBR8IagmzuT3Y="
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "MC0CFQCF6PW5uSW/sHqsAAeztl9Tu5sqbQIUS9JwmB82emeSu4qnceqEIfHyL+U="
    } ],
    "http://purl.org/nanopub/x/signedBy" : [ {
      "@id" : "https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB"
    } ]
  }, {
    "@id" : "https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB",
    "http://www.w3.org/ns/prov#specializationOf" : [ {
      "@id" : "https://github.com/tkuhn/bio2rdf2nanopub"
    } ],
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "http://orcid.org/0000-0002-1267-0234"
    } ]
  }, {
    "@id" : "https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11",
    "http://purl.org/dc/terms/identifier" : [ {
      "@value" : "3c184e6c-ceb8-4275-a679-71dfbdac2a11"
    } ],
    "http://www.w3.org/ns/prov#used" : [ {
      "@id" : "https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349"
    } ],
    "http://www.w3.org/ns/prov#wasAssociatedWith" : [ {
      "@id" : "https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB"
    } ],
    "http://www.w3.org/ns/prov#wasStartedBy" : [ {
      "@id" : "http://orcid.org/0000-0002-1267-0234"
    } ]
  }, {
    "@id" : "https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349",
    "http://purl.org/dc/terms/isVersionOf" : [ {
      "@id" : "https://github.com/tkuhn/bio2rdf2nanopub"
    } ],
    "http://purl.org/pav/version" : [ {
      "@value" : "eda7951a5f6c622c5d2132f50c3093138484a349"
    } ],
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "http://orcid.org/0000-0002-1267-0234"
    } ]
  } ],
  "@id" : "http://bio2rdf.org/drugbank_resource:DB00673_DB01285_nanopub.RAy6-IDEPhdziQeB9cArgySyA1ps67Qia4-kzvFxHPqlw#publicationInfo"
} ]